Research To Practice | Oncology Videos

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia | Faculty Presentation 1: Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with Acute Myeloid Leukemia (AML) — Courtney D DiNardo, MD, MSCE CME information and select publications

Featuring perspectives from Dr Naval Daver and Dr Courtney D DiNardo, including the following topics: Introduction (0:00) Available and Emerging Nontargeted Therapies for Acute Myeloid Leukemia (AML) —Dr Daver (6:47) Current and Emerging Role of Biomarker-Directed Therapeutic Approaches for Patients with AML —Dr DiNardo (32:58) CME information and select publications

Featuring perspectives from Dr Julia Foldi, Dr Laura Huppert, Dr Rita Nanda, Dr Saba Shaikh and Dr Sara M Tolaney, including the following topics: Introduction: Overview of metastatic triple-negative breast cancer (mTNBC) Current and emerging strategies for patients with mTNBC (0:00) First-line treatment of mTNBC — Chemotherapy with or without immunotherapy Case: A woman in her early 60s with a history of well-controlled HIV is diagnosed with mTNBC — Dr Shaikh (6:10) Case: A woman in her mid 40s with de novo mTNBC — Dr Huppert (20:41) Case: A woman in her late 50s with mTNBC receives up-front pembrolizumab/chemotherapy — Dr Foldi (42:15) Antibody-drug conjugates (ADCs) in the management of mTNBC ADCs in the management of mTNBC; sequencing of these agents and ongoing investigations (51:45) Case: A woman in her early 50s with mTNBC receives first-line chemotherapy/immune checkpoint inhibitor followed by sacituzumab govitecan — Dr Shaikh (1:05:32) Case: A woman in her late 30s with mTNBC receives sacituzumab govitecan — Dr Huppert (1:14:21) Case: A woman in her early 40s with mTNBC (IHC 1+) with sacituzumab govitecan-intolerant disease experiences an excellent response to trastuzumab deruxtecan (T-DXd) — Dr Foldi (1:27:30) Case: A woman in her mid 50s with HER2-low metastatic breast cancer receives T-DXd — Dr Shaikh (1:42:00) PARP inhibition for the treatment of mTNBC Efficacy and tolerability of olaparib in patients with a germline BRCA mutation and HER2-negative breast cancer (1:49:49) Case: A woman in her mid 30s with mTNBC receives olaparib — Dr Foldi (1:54:28) Case: A woman in her mid 60s with mTNBC and a BRCA mutation receives olaparib — Dr Huppert (1:59:11) Case: A woman in her mid 40s with a BRCA1 germline mutation and mTNBC receives olaparib — Dr Shaikh (2:03:45) CME information and select publications

Featuring perspectives from Dr Matthew D Galsky, including the following topics: HER2 alterations in urothelial cancer and current targeting approaches (0:00) Key findings supporting the use of trastuzumab deruxtecan for patients with HER2-overexpressing cancers as part of the Phase II DESTINY-PanTumor02 study (9:39) Targeting of HER2 using disitamab vedotin both as a monotherapy and in combination with other treatments (14:31) Case: A man in his late 70s with a history of non-muscle-invasive bladder cancer who develops HER2-positive lung metastases (28:57) Case: A man in his late 60s who receives disitamab vedotin for HER2 IHC 2+ metastatic urothelial cancer (36:25) Enfortumab vedotin and pembrolizumab as first-line or neoadjuvant therapy for targeting HER2-expressing cancers (39:34) Future direction of HER2-targeting therapies for urothelial bladder cancer (1:02:48) CME information and select publications

Featuring a slide presentation and related discussion from Dr Sunnie Kim, including the following topics: Year in Review: Novel Treatments and Strategies in Gastroesophageal Cancer — Dr Kim (0:00) Case: A man in his mid 50s with poorly differentiated mismatch repair-deficient advanced gastric cancer receives first-line nivolumab/ipilimumab (49:22) Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who experienced disease progression on FOLFOX/trastuzumab receives trastuzumab deruxtecan (54:48) Case: A man in his mid 60s with Stage IV, PD-L1-positive GEJ adenocarcinoma (58:11) Case: A man in his early 40s with metastatic CLDN18.2-positive gastric/GEJ adenocarcinoma receives zolbetuximab (1:01:10) CME information and select publications

Featuring perspectives from Prof Eric Van Cutsem, including the following topics: Immune Checkpoint Inhibitors in Localized Gastroesophageal (GE) Cancers Introduction (0:00) Case: A man in his mid 50s with localized, poorly differentiated signet ring, mismatch repair-deficient advanced gastric adenocarcinoma — Sunnie Kim, MD (3:39) HER2-Positive GE Cancers Case: A man in his early 70s with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma and disease progression on FOLFOX/trastuzumab (PD-L1 CPS 0) — Dr Kim (19:22) First-Line Treatment of Metastatic Gastric and GEJ Adenocarcinoma Case: A man in his early 40s who presents with metastatic GEJ adenocarcinoma (CLDN18.2-positive, PD-L1 CPS 2) in visceral crisis from lung metastases — Dr Kim (38:53) Case: A man in his mid 60s with metastatic GEJ adenocarcinoma (PD-L1 CPS 20) — Dr Kim (50:50) CME information and select publications

Featuring perspectives from Dr Ruben A Mesa, including the following topics: Introduction: Journal Club with Dr Mesa (0:00) Case: A woman in her mid 80s with an interesting and unusual presentation of primary myelofibrosis — Bhavana (Tina) Bhatnagar, DO (25:33) Case: A man in his early 70s, asymptomatic, with lower-risk primary MF (JAK2 V617F mutation) — Susannah Friemel, MD (29:42) Case: A woman in her early 80s with pancytopenia and palpable spleen who is diagnosed with primary MF — Jeanne Palmer, MD (35:08) Case: A man in his early 70s with multiple comorbidities and MF (CALR mutation) who receives ruxolitinib 10 mg BID — Ranju Gupta, MD (42:40) ASH 2023 Review (46:13) Faculty Survey (55:41) CME information and select publications

Featuring perspectives from Dr Carlos M de Castro III, Prof Alexander Röth and Dr Ilene Ceil Weitz, including the following topics: Introduction: A Paroxysmal Nocturnal Hemoglobinuria (PNH) Audio Primer for General Medical Oncologists (0:00) Biology and Current Clinical Management of PNH (36:35) Future Directions in PNH Management (55:34) Tolerability and Other Practical Considerations with Available and Emerging Treatments for PNH (1:14:26) CME information and select publications

Featuring an interview with Dr Emmanuel S Antonarakis, including the following topics: Perspectives on advances in the management of prostate cancer over the last decade (0:00) Nonmetastatic high-risk prostate cancer and androgen deprivation therapy (ADT) intensification with abiraterone: Insights from the STAMPEDE trial (7:39) EMBARK: A Phase III trial of enzalutamide or placebo with leuprolide acetate and enzalutamide monotherapy for high-risk biochemically recurrent prostate cancer (15:25) Quality of life and preservation of sexual function with enzalutamide monotherapy compared to ADT alone or enzalutamide with ADT (20:20) Management of locally advanced prostate cancer with and without biochemical recurrence (23:58) PRESTO trial of ADT intensification with apalutamide with or without abiraterone for high-risk biochemically relapsed prostate cancer (30:35) CDK4/6 inhibitors, proteolysis-targeting chimeras and other novel therapeutic approaches for targeting androgen receptor signaling in prostate cancer (31:41) Choice of endocrine partner with ADT and incorporation of docetaxel in the treatment of metastatic hormone-sensitive prostate cancer (35:38) Other potential novel therapeutic strategies for prostate cancer (42:28) Integration of genomic testing for patients with prostate cancer; PARP inhibitor combinations for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (43:57) Incorporation of radiopharmaceuticals (ie, lutetium Lu 177 vipivotide tetraxetan, radium-223) into the management of prostate cancer (52:49) Perspectives on the results of the Phase III CONTACT-02 trial evaluating cabozantinib in combination with atezolizumab for mCRPC (57:44) CME information and select publications

Featuring perspectives from Dr Naveen Pemmaraju, including the following topics: Recent developments in management approaches for myelofibrosis prior to ASH 2023 (0:00) Updated data with navitoclax in combination with ruxolitinib for patients with myelofibrosis (12:35) Key findings with pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve myelofibrosis in the Phase III MANIFEST-2 study (22:21) Long-term follow-up from the Phase I/III XPORT-MF-034 trial of selinexor with ruxolitinib for JAK inhibitor-naïve myelofibrosis (29:10) Effect of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with ruxolitinib in the expanded-access JUMP study (34:33) Results from the Phase III FREEDOM-2 study of fedratinib for patients with myelofibrosis after prior ruxolitinib (40:38) Landmark survival analysis of the Phase III PERSIST-2 trial evaluating pacritinib versus best available therapy in patients with myelofibrosis and thrombocytopenia (43:08) Retrospective analysis of the PAC203 and PERSIST-2 studies of pacritinib for cytopenic myelofibrosis (47:56) Longitudinal assessment of transfusion intensity in patients who received momelotinib for myelofibrosis in the Phase III SIMPLIFY-1 and MOMENTUM trials (52:48) Two-year follow-up from the Phase II REVIVE study of rusfertide in phlebotomy-dependent patients with polycythemia vera (55:18) Available Phase I/II data with the novel agent zilurgisertib with or without ruxolitinib in patients with anemia due to myelofibrosis (58:56) CME information and select publications